Early- and advanced non-enzymatic glycation in diabetic vascular complications: The search for therapeutics

Amino Acids

Volumn 42, Issue 4, 2012, Pages 1193-1204

  Schalkwijk, Casper G ^a   Miyata, Toshio ^b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

AGEs; Amadori albumin; Diabetes; Non enzymatic glycation; Vascular complications

Indexed keywords

2 [3 CHLOROPHENYLAMINO]PHENYL ACETIC ACID; 2 ISOPROPYLIDENEHYDRAZONO 4 OXO 5 THIAZOLIDINYLACETANILIDE; 3 DEOXYGLUCOSONE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALAGEBRIUM; ALBUMIN; ALT 946; AMINOGUANIDINE; ANGIOTENSIN ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; BENFOTIAMINE; CYANOCOBALAMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EXO 226; GLUCOSE; GLY 230; GLYOXAL; LR 90; METHYLGLYOXAL; NORPHENAZONE; PROTEIN KINASE C; PYRIDOXAMINE; PYRIDOXINE; R 147176; ROSIGLITAZONE; THIAMINE; THIOCTIC ACID; TM 2002; UNCLASSIFIED DRUG; UNINDEXED DRUG; PROTEIN;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ALBUMINURIA; ANEMIA; ANTIDIABETIC ACTIVITY; ATHEROSCLEROSIS; BIOACCUMULATION; BRAIN INFARCTION; CARDIOVASCULAR DISEASE; CAUSAL ATTRIBUTION; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIABETOGENESIS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; EXTRACELLULAR MATRIX; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; INTRACELLULAR SIGNALING; KIDNEY FIBROSIS; KIDNEY INJURY; LIVER FUNCTION TEST; MICROALBUMINURIA; NEOVASCULARIZATION (PATHOLOGY); NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN PROTEIN INTERACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; SYSTOLIC HYPERTENSION; TISSUE INJURY; UNSPECIFIED SIDE EFFECT; VASCULITIS; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GLYCOSYLATION; METABOLISM;

ANIMALS; DIABETIC ANGIOPATHIES; GLYCOSYLATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; PROTEINS;

EID: 84862652504     PISSN: 09394451     EISSN: 14382199     Source Type: Journal    
DOI: 10.1007/s00726-010-0779-9     Document Type: Review

References (115)

1. Alkhalaf A, Klooster A, van Oeveren W, Achenbach U, Kleefstra N, Slingerland RJ, Mijnhout GS, Bilo HJ, Gans RO, Navis GJ, Bakker SJ (2010) A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care 33(7):1598-1601
2. Amore A, Cirina P, Mitola S, Peruzzi L, Gianoglio B, Rabbone I, Sacchetti C, Cerutti F, Grillo C, Coppo R (1997) Nonenzymatically glycated albumin (Amadori adducts) enhances nitric oxide synthase activity and gene expression in endothelial cells. Kidney Int 51:27-35 (Pubitemid 27064518)
3. Asif M, Egan J, Vasan S, Jyothirmayi GN, Masurekar MR, Lopez S, Williams C, Torres RL, Wagle D, Ulrich P, Cerami A, Brines M, Regan TJ (2000) An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness. Proc Natl Acad Sci USA 97:2809-2813 (Pubitemid 30159253)
4. Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ (2003) Prevention of incipient diabetic nephropathy by highdose thiamine and benfotiamine. Diabetes 52:2110-2120 (Pubitemid 36919806)
5. Baynes JW, Thorpe SR (2000) Glycoxidation and lipoxidation in atherogenesis. Free Radic Biol Med 28:1708-1716 (Pubitemid 30628657)
6. Bierhaus A, Nawroth PP (2009) Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologia 52:2251-2263
7. Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J, Hong M, Luther T, Henle T, Kloting I, Morcos M, Hofmann M, Tritschler H, Weigle B, Kasper M, Smith M, Perry G, Schmidt AM, Stern DM, Haring HU, Schleicher E, Nawroth PP (2001) Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 50:2792-2808 (Pubitemid 33733131)
8. Bierhaus A, Haslbeck KM, Humpert PM, Liliensiek B, Dehmer T, Morcos M, Sayed AA, Andrassy M, Schiekofer S, Schneider JG, Schulz JB, Heuss D, Neundorfer B, Dierl S, Huber J, Tritschler H, Schmidt AM, Schwaninger M, Haering HU, Schleicher E, Kasper M, Stern DM, Arnold B, Nawroth PP (2004) Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. J Clin Invest 114:1741-1751 (Pubitemid 40385530)
9. Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, Stern DM, Nawroth PP (2005) Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 83:876-886 (Pubitemid 41598688)
10. Bolton WK, Cattran DC, Williams ME, Adler SG, Appel GB, Cartwright K, Foiles PG, Freedman BI, Raskin P, Ratner RE, Spinowitz BS, Whittier FC, Wuerth JP (2004) Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 24:32-40 (Pubitemid 38250484)
11. Brouwers O, Niessen PM, Haenen G, Miyata T, Brownlee M, Stehouwer CD, De Mey JG, Schalkwijk CG (2010) Hyperglycaemia- induced impairment of endothelium-dependent vasorelaxation in rat mesenteric arteries is mediated by intracellular methylglyoxal levels in a pathway dependent on oxidative stress. Diabetologia 53:989-1000
12. Brownlee M (2005) The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54:1615-1625 (Pubitemid 40770750)
13. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A (1986) Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232:1629-1632 (Pubitemid 16095602)
14. Cai W, He JC, Zhu L, Chen X, Striker GE, Vlassara H (2008) AGEreceptor- 1 counteracts cellular oxidant stress induced by AGEs via negative regulation of p66shc-dependent FKHRL1 phosphorylation. Am J Physiol Cell Physiol 294:C145-C152
15. Cai W, Torreggiani M, Zhu L, Chen X, He JC, Striker GE, Vlassara H (2010) AGER1 regulates endothelial cell NADPH oxidasedependent oxidant stress via PKC-delta: implications for vascular disease. Am J Physiol Cell Physiol 298:C624-C634
16. Chen S, Jim B, Ziyadeh FN (2003) Diabetic nephropathy and transforming growth factor-beta: transforming our view of glomerulosclerosis and fibrosis build-up. Semin Nephrol 23:532-543 (Pubitemid 38030087)
17. Chetyrkin SV, Zhang W, Hudson BG, Serianni AS, Voziyan PA (2008) Pyridoxamine protects proteins from functional damage by 3-deoxyglucosone: mechanism of action of pyridoxamine. Biochemistry 47:997-1006
18. Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, Pober JS, Wick TM, Konkle BA, Schwartz BS, Barnathan ES, McCrae KR, Hug BA, Schmidt AM, Stern DM (1998) Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 91:3527-3561 (Pubitemid 28225719)
19. Clements RS Jr, Robison WG Jr, Cohen MP (1998) Anti-glycated albumin therapy ameliorates early retinal microvascular pathology in db/db mice. J Diabetes Complications 12:28-33 (Pubitemid 28028759)
20. Cohen MP, Hud E, Wu VY (1994) Amelioration of diabetic nephropathy by treatment with monoclonal antibodies against glycated albumin. Kidney Int 45:1673-1679 (Pubitemid 24207503)
21. Cohen MP, Clements RS, Cohen JA, Shearman CW (1996) Glycated albumin promotes a generalized vasculopathy in the db/db mouse. Biochem Biophys Res Commun 218:72-75 (Pubitemid 26034491)
22. Cohen MP, Masson N, Hud E, Ziyadeh F, Han DC, Clements RS (2000) Inhibiting albumin glycation ameliorates diabetic nephropathy in the db/db mouse. Exp Nephrol 8:135-143 (Pubitemid 30313589)
23. Cohen MP, Ziyadeh FN, Hong SW, Shearman CW, Hud E, Lautenslager GT, Iglesias-de la Cruz MC, Chen S (2002) Inhibiting albumin glycation in vivo ameliorates glomerular overexpression of TGF-beta1. Kidney Int 61:2025-2032 (Pubitemid 34539320)
24. Cohen MP, Chen S, Ziyadeh FN, Shea E, Hud EA, Lautenslager GT, Shearman CW (2005) Evidence linking glycated albumin to altered glomerular nephrin and VEGF expression, proteinuria, and diabetic nephropathy. Kidney Int 68:1554-1561 (Pubitemid 43169900)
25. Cohen MP, Lautenslager GT, Hud E, Shea E, Wang A, Chen S, Shearman CW (2007) Inhibiting albumin glycation attenuates dysregulation of VEGFR-1 and collagen IV subchain production and the development of renal insufficiency. Am J Physiol Renal Physiol 292:F789-F795 (Pubitemid 46220547)
26. Cohen MP, Hud E, Wu VY, Shearman CW (2008) Amelioration of diabetes-associated abnormalities in the vitreous fluid by an inhibitor of albumin glycation. Invest Ophthalmol Vis Sci 49:5089-5093
27. Coughlan MT, Thorburn DR, Penfold SA, Laskowski A, Harcourt BE, Sourris KC, Tan AL, Fukami K, Thallas-Bonke V, Nawroth PP, Brownlee M, Bierhaus A, Cooper ME, Forbes JM (2009) RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J Am Soc Nephrol 20:742-752
28. Degenhardt TP, Alderson NL, Arrington DD, Beattie RJ, Basgen JM, Steffes MW, Thorpe SR, Baynes JW (2002) Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin- diabetic rat. Kidney Int 61:939-950 (Pubitemid 34175462)
29. Dolhofer R, Wieland OH (1980) Increased glycosylation of serum albumin in diabetes mellitus. Diabetes 29:417-422 (Pubitemid 11018459)
30. Du X, Edelstein D, Brownlee M (2008) Oral benfotiamine plus alphalipoic acid normalises complication-causing pathways in type 1 diabetes. Diabetologia 51:1930-1932
31. Figarola JL, Scott S, Loera S, Tessler C, Chu P, Weiss L, Hardy J, Rahbar S (2003) LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin- diabetic rats. Diabetologia 46:1140-1152 (Pubitemid 37041245)
32. Forbes JM, Soulis T, Thallas V, Panagiotopoulos S, Long DM, Vasan S, Wagle D, Jerums G, Cooper ME (2001) Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia 44:108-114 (Pubitemid 32141892)
33. Forbes JM, Cooper ME, Thallas V, Burns WC, Thomas MC, Brammar GC, Lee F, Grant SL, Burrell LA, Jerums G, Osicka TM (2002) Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 51:3274-3282 (Pubitemid 35246974)
34. Forbes JM, Yee LT, Thallas V, Lassila M, Candido R, Jandeleit- Dahm KA, Thomas MC, Burns WC, Deemer EK, Thorpe SM, Cooper ME, Allen TJ (2004) Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 53:1813-1823 (Pubitemid 38857040)
35. Forbes JM, Thorpe SR, Thallas-Bonke V, Pete J, Thomas MC, Deemer ER, Bassal S, El Osta A, Long DM, Panagiotopoulos S, Jerums G, Osicka TM, Cooper ME (2005) Modulation of soluble receptor for advanced glycation end products by angiotensin converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol 16(8):2363-2672
36. Freedman BI, Wuerth JP, Cartwright K, Bain RP, Dippe S, Hershon K, Mooradian AD, Spinowitz BS (1999) Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). Control Clin Trials 20:493-510 (Pubitemid 29460926)
37. Genuth S, Sun W, Cleary P, Sell DR, Dahms W, Malone J, Sivitz W, Monnier VM (2005) Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes 54:3103-3111 (Pubitemid 43334362)
38. Giardino I, Edelstein D, Brownlee M (1994) Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. J Clin Invest 94:110-117
39. Goh SY, Cooper ME (2008) Clinical review: the role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 93:1143-1152 (Pubitemid 351519698)
40. Goldin A, Beckman JA, Schmidt AM, Creager MA (2006) Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114:597-605 (Pubitemid 44199649)
41. Haitoglou CS, Tsilibary EC, Brownlee M, Charonis AS (1992) Altered cellular interactions between endothelial cells and nonenzymatically glucosylated laminin/type IV collagen. J Biol Chem 267:12404-12407
42. Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, Lin J, Bierhaus A, Nawroth P, Hannak D, Neumaier M, Bergfeld R, Giardino I, Brownlee M (2003) Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 9:294-299 (Pubitemid 36362784)
43. Hattori Y, Suzuki M, Hattori S, Kasai K (2002) Vascular smooth muscle cell activation by glycated albumin (Amadori adducts). Hypertension 39:22-28 (Pubitemid 34098083)
44. Higai K, Shimamura A, Matsumoto K (2006) Amadori-modified glycated albumin predominantly induces E-selectin expression on human umbilical vein endothelial cells through NADPH oxidase activation. Clin Chim Acta 367:137-143
45. House AA, Eliasziw M, Cattran DC, Churchill DN, Oliver MJ, Fine A, Dresser GK, Spence JD (2010) Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA 303:1603-1609
46. Hudson BI, Bucciarelli LG, Wendt T, Sakaguchi T, Lalla E, Qu W, Lu Y, Lee L, Stern DM, Naka Y, Ramasamy R, Yan SD, Yan SF, D'Agati V, Schmidt AM (2003) Blockade of receptor for advanced glycation endproducts: a new target for therapeutic intervention in diabetic complications and inflammatory disorders. Arch Biochem Biophys 419:80-88 (Pubitemid 37272161)
47. Izuhara Y, Nangaku M, Inagi R, Tominaga N, Aizawa T, Kurokawa K, Miyata T, van Ypersele DS (2005) Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. J Am Soc Nephrol 16:3631-3641 (Pubitemid 46211284)
48. Izuhara Y, Nangaku M, Takizawa S, Takahashi S, Shao J, Oishi H, Kobayashi H, van Ypersele DS, Miyata T (2008) A novel class of advanced glycation inhibitors ameliorates renal and cardiovascular damage in experimental rat models. Nephrol Dial Transplant 23:497-509 (Pubitemid 351767619)
49. Jaleel A, Halvatsiotis P, Williamson B, Juhasz P, Martin S, Nair KS (2005) Identification of Amadori-modified plasma proteins in type 2 diabetes and the effect of short-term intensive insulin treatment. Diabetes Care 28:645-652 (Pubitemid 40315326)
50. Karachalias N, Babaei-Jadidi R, Rabbani N, Thornalley PJ (2010) Increased protein damage in renal glomeruli, retina, nerve, plasma and urine and its prevention by thiamine and benfotiamine therapy in a rat model of diabetes. Diabetologia 53:1506-1516
51. Kass DA, Shapiro EP, Kawaguchi M, Capriotti AR, Scuteri A, de Groof RC, Lakatta EG (2001) Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 104:1464-1470 (Pubitemid 32917336)
52. Kennedy L, Solano MP, Meneghini L, Lo M, Cohen MP (2010) Antiglycation and anti-albuminuric effects of GLY-230 in human diabetes. Am J Nephrol 31:110-116
53. Khalifah RG, Chen Y, Wassenberg JJ (2005) Post-Amadori AGE inhibition as a therapeutic target for diabetic complications: a rational approach to second-generation Amadorin design. Ann N Y Acad Sci 1043:793-806 (Pubitemid 41123974)
54. Lee HJ, Howell SK, Sanford RJ, Beisswenger PJ (2005) Methylglyoxal can modify GAPDH activity and structure. Ann N Y Acad Sci 1043:135-145 (Pubitemid 41123899)
55. Little WC, Zile MR, Kitzman DW, Hundley WG, O'Brien TX, de Groof RC (2005) The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail 11:191-195 (Pubitemid 40462421)
56. Lu C, He JC, Cai W, Liu H, Zhu L, Vlassara H (2004) Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells. Proc Natl Acad Sci USA 101:11767-11772 (Pubitemid 39099304)
57. McCance DR, Dyer DG, Dunn JA, Bailie KE, Thorpe SR, Baynes JW, Lyons TJ (1993) Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest 91:2470-2478 (Pubitemid 23182498)
58. McNulty M, Mahmud A, Feely J (2007) Advanced glycation endproducts and arterial stiffness in hypertension. Am J Hypertens 20:242-247 (Pubitemid 46283356)
59. Miyata T, Ishikawa S, Asahi K, Inagi R, Suzuki D, Horie K, Tatsumi K, Kurokawa K (1999) 2-Isopropylidenehydrazono-4-oxo- thiazolidin-5-ylacetanilide (OPB-9195) treatment inhibits the development of intimal thickening after balloon injury of rat carotid artery: role of glycoxidation and lipoxidation reactions in vascular tissue damage. FEBS Lett 445:202-206 (Pubitemid 29101561)
60. Miyata T, van Ypersele DS, Imasawa T, Yoshino A, Ueda Y, Ogura H, Kominami K, Onogi H, Inagi R, Nangaku M, Kurokawa K (2001) Glyoxalase I deficiency is associated with an unusual level of advanced glycation end products in a hemodialysis patient. Kidney Int 60:2351-2359 (Pubitemid 33070479)
61. Miyata T, van Ypersele DS, Ueda Y, Ichimori K, Inagi R, Onogi H, Ishikawa N, Nangaku M, Kurokawa K (2002) Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol 13:2478-2487
62. Mizutani K, Ikeda K, Tsuda K, Yamori Y (2002) Inhibitor for advanced glycation end products formation attenuates hypertension and oxidative damage in genetic hypertensive rats. J Hypertens 20:1607-1614 (Pubitemid 34921185)
63. Myint KM, Yamamoto Y, Doi T, Kato I, Harashima A, Yonekura H, Watanabe T, Shinohara H, Takeuchi M, Tsuneyama K, Hashimoto N, Asano M, Takasawa S, Okamoto H, Yamamoto H (2006) RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin. Diabetes 55:2510-2522 (Pubitemid 44871151)
64. Nakamura S, Makita Z, Ishikawa S, Yasumura K, Fujii W, Yanagisawa K, Kawata T, Koike T (1997) Progression of nephropathy in spontaneous diabetic rats is prevented by OPB- 9195, a novel inhibitor of advanced glycation. Diabetes 46:895-899 (Pubitemid 27188270)
65. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, Elliston K, Stern D, Shaw A (1992) Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267:14998-15004
66. Price DL, Rhett PM, Thorpe SR, Baynes JW (2001) Chelating activity of advanced glycation end-product inhibitors. J Biol Chem 276:48967-48972
67. Queisser MA, Yao D, Geisler S, Hammes HP, Lochnit G, Schleicher ED, Brownlee M, Preissner KT (2010) Hyperglycemia impairs proteasome function by methylglyoxal. Diabetes 59:670-678
68. Rabbani N, Alam SS, Riaz S, Larkin JR, Akhtar MW, Shafi T, Thornalley PJ (2009) High-dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double-blind placebo-controlled pilot study. Diabetologia 52:208-212
69. Rahbar S, Figarola JL (2003) Novel inhibitors of advanced glycation endproducts. Arch Biochem Biophys 419:63-79 (Pubitemid 37287559)
70. Rosca MG, Mustata TG, Kinter MT, Ozdemir AM, Kern TS, Szweda LI, Brownlee M, Monnier VM, Weiss MF (2005) Glycation of mitochondrial proteins from diabetic rat kidney is associated with excess superoxide formation. Am J Physiol Renal Physiol 289:F420-F430 (Pubitemid 41003672)
71. Sabbatini M, Sansone G, Uccello F, Giliberti A, Conte G, Andreucci VE (1992) Early glycosylation products induce glomerular hyperfiltration in normal rats. Kidney Int 42:875-881
72. Sakai H, Jinde K, Suzuki D, Yagame M, Nomoto Y (1996) Localization of glycated proteins in the glomeruli of patients with diabetic nephropathy. Nephrol Dial Transplant 11(Suppl 5):66-71 (Pubitemid 27062915)
73. Schalkwijk CG, Stehouwer CD (2005) Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci 109:143-159 (Pubitemid 41117297)
74. Schalkwijk CG, Ligtvoet N, Twaalfhoven H, Jager A, Blaauwgeers HG, Schlingemann RO, Tarnow L, Parving HH, Stehouwer CD, van Hinsbergh VW (1999) Amadori albumin in type 1 diabetic patients: correlation with markers of endothelial function, association with diabetic nephropathy, and localization in retinal capillaries. Diabetes 48:2446-2453 (Pubitemid 30395438)
75. Schmidt AM, Hasu M, Popov D, Zhang JH, Chen J, Yan SD, Brett J, Cao R, Kuwabara K, Costache G (1994) Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc Natl Acad Sci USA 91:8807-8811
76. Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, Cao R, Yan SD, Brett J, Stern D (1995) Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 96:1395-1403
77. Schmidt AM, Yan SD, Wautier JL, Stern D (1999) Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 19(84):489-497 (Pubitemid 29138585)
78. Schmidt AM, Yan SD, Yan SF, Stern DM (2001) The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 108:949-955 (Pubitemid 32946067)
79. Shinohara M, Thornalley PJ, Giardino I, Beisswenger P, Thorpe SR, Onorato J, Brownlee M (1998) Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. J Clin Invest 101:1142-1147 (Pubitemid 28125293)
80. Sims TJ, Rasmussen LM, Oxlund H, Bailey AJ (1996) The role of glycation cross-links in diabetic vascular stiffening. Diabetologia 39:946-951 (Pubitemid 26249114)
81. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, Howard BV, Kirkman MS, Kosiborod M, Reaven P, Sherwin RS (2009) Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol 53:298-304
82. Soro-Paavonen A, Watson AM, Li J, Paavonen K, Koitka A, Calkin AC, Barit D, Coughlan MT, Drew BG, Lancaster GI, Thomas M, Forbes JM, Nawroth PP, Bierhaus A, Cooper ME, Jandeleit- Dahm KA (2008) Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 57:2461-2469
83. Soro-Paavonen A, Zhang WZ, Venardos K, Coughlan MT, Harris E, Tong DC, Brasacchio D, Paavonen K, Chin-Dusting J, Cooper ME, Kaye D, Thomas MC, Forbes JM (2010) Advanced glycation end-products induce vascular dysfunction via resistance to nitric oxide and suppression of endothelial nitric oxide synthase. J Hypertens 28(4):780-788
84. Stirban A, Negrean M, Stratmann B, Gawlowski T, Horstmann T, Gotting C, Kleesiek K, Mueller-Roesel M, Koschinsky T, Uribarri J, Vlassara H, Tschoepe D (2006) Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care 29:2064-2071 (Pubitemid 44871188)
85. Takizawa S, Izuhara Y, Kitao Y, Hori O, Ogawa S, Morita Y, Takagi S, van Ypersele DS, Miyata T (2007) A novel inhibitor of advanced glycation and endoplasmic reticulum stress reduces infarct volume in rat focal cerebral ischemia. Brain Res 1183:124-137 (Pubitemid 350088683)
86. Takizawa S, Dan T, Uesugi T, Nagata E, Takagi S, van Ypersele DS, Miyata T (2009) A sartan derivative with a very low angiotensin II receptor affinity ameliorates ischemic cerebral damage. J Cereb Blood Flow Metab 29:1665-1672
87. Tan KC, Chow WS, Tso AW, Xu A, Tse HF, Hoo RL, Betteridge DJ, Lam KS (2007) Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes. Diabetologia 50:1819-1825 (Pubitemid 47222871)
88. Thallas-Bonke V, Lindschau C, Rizkalla B, Bach LA, Boner G, Meier M, Haller H, Cooper ME, Forbes JM (2004) Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathway. Diabetes 53:2921-2930 (Pubitemid 39425918)
89. The Diabetes Control Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329:977-986
90. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2000) Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 342:381-389
91. Thornalley PJ (2005a) Dicarbonyl intermediates in the maillard reaction. Ann N Y Acad Sci 1043:111-117 (Pubitemid 41123896)
92. Thornalley PJ (2005b) The potential role of thiamine (vitamin B1) in diabetic complications. Curr Diabetes Rev 1:287-298
93. Thornalley PJ, Minhas HS (1999) Rapid hydrolysis and slow alpha, beta-dicarbonyl cleavage of an agent proposed to cleave glucosederived protein cross-links. Biochem Pharmacol 57:303-307 (Pubitemid 29056208)
94. Thornalley PJ, Rabbani N (2010) Therapy: Vitamin B(6), B(9) and B(12) in diabetic nephropathy-beware. Nat Rev Endocrinol 6:477-478
95. Throckmorton DC, Brogden AP, Min B, Rasmussen H, Kashgarian M (1995) PDGF and TGF-beta mediate collagen production by mesangial cells exposed to advanced glycosylation end products. Kidney Int 48:111-117
96. Tsujita K, Shimomura H, Kawano H, Hokamaki J, Fukuda M, Yamashita T, Hida S, Nakamura Y, Nagayoshi Y, Sakamoto T, Yoshimura M, Arai H, Ogawa H (2004) Effects of edaravone on reperfusion injury in patients with acute myocardial infarction. Am J Cardiol 94:481-484 (Pubitemid 39120000)
97. UK Prospective Diabetes Study (UKPDS) Group (1995) Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years (UKPDS 13). BMJ 310:83-88
98. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853
99. Vasan S, Zhang X, Zhang X, Kapurniotu A, Bernhagen J, Teichberg S, Basgen J, Wagle D, Shih D, Terlecky I, Bucala R, Cerami A, Egan J, Ulrich P (1996) An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 382:275-278 (Pubitemid 26251366)
100. Vlassara H, Bucala R (1996) Recent progress in advanced glycation and diabetic vascular disease: role of advanced glycation end product receptors. Diabetes 45(Suppl 3):S65-S66
101. Vlassara H, Fuh H, Makita Z, Krungkrai S, Cerami A, Bucala R (1992) Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proc Natl Acad Sci USA 89:12043-12047 (Pubitemid 23004781)
102. Wang K, Zhou Z, Zhang M, Fan L, Forudi F, Zhou X, Qu W, Lincoff AM, Schmidt AM, Topol EJ, Penn MS (2006) Peroxisome proliferator-activated receptor gamma down-regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury model. J Pharmacol Exp Ther 317:37-43
103. Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, Lu Y, Bucciarelli LG, Rong LL, Moser B, Markowitz GS, Stein G, Bierhaus A, Liliensiek B, Arnold B, Nawroth PP, Stern DM, D'Agati VD, Schmidt AM (2003) RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 162:1123-1137 (Pubitemid 36350658)
104. Wilkinson-Berka JL, Kelly DJ, Koerner SM, Jaworski K, Davis B, Thallas V, Cooper ME (2002) ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2)27 rat. Diabetes 51:3283-3289 (Pubitemid 35246975)
105. Williams ME, Bolton WK, Khalifah RG, Degenhardt TP, Schotzinger RJ, McGill JB (2007) Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am J Nephrol 27:605-614 (Pubitemid 350014947)
106. Wolf G, Ritz E (2005) Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 67:799-812 (Pubitemid 41623305)
107. Wolffenbuttel BH, Boulanger CM, Crijns FR, Huijberts MS, Poitevin P, Swennen GN, Vasan S, Egan JJ, Ulrich P, Cerami A, Levy BI (1998) Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci USA 95:4630-4634
108. Wu L, Juurlink BH (2002) Increased methylglyoxal and oxidative stress in hypertensive rat vascular smooth muscle cells. Hypertension 39:809-814 (Pubitemid 34252881)
109. Xie J, Reverdatto S, Frolov A, Hoffmann R, Burz DS, Shekhtman A (2008) Structural basis for pattern recognition by the receptor for advanced glycation end products (RAGE). J Biol Chem 283:27255-27269
110. Yan SF, Ramasamy R, Schmidt AM (2010) The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ Res 106:842-853
111. Yao D, Taguchi T, Matsumura T, Pestell R, Edelstein D, Giardino I, Suske G, Rabbani N, Thornalley PJ, Sarthy VP, Hammes HP, Brownlee M (2007) High glucose increases angiopoietin-2 transcription in microvascular endothelial cells through methylglyoxal modification of mSin3A. J Biol Chem 282(42): 31038-31045 (Pubitemid 350035169)
112. Yoshida N, Okumura K, Aso Y (2005) High serum pentosidine concentrations are associated with increased arterial stiffness and thickness in patients with type 2 diabetes. Metabolism 54:345-350 (Pubitemid 40250094)
113. Zhang Q, Tang N, Schepmoes AA, Phillips LS, Smith RD, Metz TO (2008) Proteomic profiling of nonenzymatically glycated proteins in human plasma and erythrocyte membranes. J Proteome Res 7:2025-2032
114. Zimmet P, Alberti KG, Shaw J (2001) Global and societal implications of the diabetes epidemic. Nature 414:782-787 (Pubitemid 34000780)
115. Ziyadeh FN (2004) Mediators of diabetic renal disease: the case for tgf-Beta as the major mediator. J Am Soc Nephrol 15(Suppl 1):S55-S57 (Pubitemid 38018457)